BRIM Biotechnology (TPE:6885) Common Stock: NT$1,332.14 Mil (As of Dec. 2025)


TPE:6885 BRIM Biotechnology Inc TPE:6885
40 GF Score
Price NT$21.75
GF Value NT$486.91
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BRIM Biotechnology Common Stock?

BRIM Biotechnology TPE:6885 -0.46% 40 Common Stock is NT$1,332.14 Mil as of Dec. 2025. GuruFocus rates TPE:6885 with a GF Score™ of 40/100 and a GF Value™ of NT$486.91 (Possible Value Trap). The stock has 4 warning signs investors should review.

BRIM Biotechnology's quarterly common stock increased from Jun. 2025 (NT$1,323.10 Mil) to Sep. 2025 (NT$1,332.14 Mil) but then stayed the same from Sep. 2025 (NT$1,332.14 Mil) to Dec. 2025 (NT$1,332.14 Mil).

BRIM Biotechnology's annual common stock increased from Dec. 2023 (NT$1,157.54 Mil) to Dec. 2024 (NT$1,315.13 Mil) and increased from Dec. 2024 (NT$1,315.13 Mil) to Dec. 2025 (NT$1,332.14 Mil).

BRIM Biotechnology Common Stock Historical Data

* Premium members only.

The historical data trend for BRIM Biotechnology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRIM Biotechnology Common Stock Chart

BRIM Biotechnology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 692.54 932.54 1,157.54 1,315.13 1,332.14

BRIM Biotechnology Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,315.13 1,323.10 1,323.10 1,332.14 1,332.14
TPE:6885
40GF Score
BRIM Biotechnology Inc TPE:6885
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRIM Biotechnology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of NT$1,332.14 Mil mean?
BRIM Biotechnology (TPE:6885) has a Common Stock of NT$1,332.14 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BRIM Biotechnology and its competitors.
Is BRIM Biotechnology's Common Stock too high?
BRIM Biotechnology's current Common Stock is NT$1,332.14 Mil. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's Common Stock compare to VRTX and REGN?
BRIM Biotechnology's Common Stock of NT$1,332.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BRIM Biotechnology and its competitors. BRIM Biotechnology's current Common Stock is NT$1,332.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current Common Stock is NT$1,332.14 Mil. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current Common Stock is NT$1,332.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?

Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued. The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91. GuruFocus considers BRIM Biotechnology to be Possible Value Trap.

Key valuation signals for TPE:6885:

  • Common Stock: NT$1,332.14 Mil
  • GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRIM Biotechnology Business Description

Address Alley 30, Lane 358, Ruiguang Road, 8th Floor, No.1, Neihu District, Taipei, TWN, 11492
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score

Get the complete analysis for TPE:6885

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$21.75
Price
NT$486.91
GF Value